ZYDELIG 150 mg, film-coated tablet 60 tablets
Active ingredients: IDÉLALISIB
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZYDELIG 150 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s)
- Marketing authorisation holder
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Leucémie lymphoïde chronique et lymphome folliculaire (maladies provoquant une production excessive continue de globules blancs anormaux), en respectant certaines conditions précisément définies. ; JOURNAL OFFICIEL ; 16/05/19
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2014
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68093737CIP72795972CIP133400927959721Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IDÉLALISIBcomprimé | 150 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.